


## Thriving Sectors: Life Sciences

Life science and cloud software companies have consistently attracted the majority of venture capital investments in the last ten years and continued to do so in 2018. Over 30% of capital raised since 2016 has gone to life science companies, with over 20 companies raising more than \$555 million. The majority of this capital was devoted to a few later-staged companies, although many earlier staged companies received funding as well, with 22 deals rounds of funding raised in amounts less than \$25 million. Within Life Sciences, the Tri-Valley fosters exceptional companies in the device space, benefiting from accommodative real estate and a diverse talent pool required as they grow. 98% of life science deals in 2018 were in the medical device space.



### Notable Life Science Investments

Year	Tri-Valley Company	Deal Size	Stage	Brief	City
2018	10x Genomics	\$50M+Debt	Series D	Genomics platform	Pleasanton
2018	BioClin (Rainier Therapeutics)	\$50M	Series B	Drug discover	San Ramon
2018	Providence Medical Tech	\$25M	Late Stage	Cervical spine surgical device	Pleasanton
2018	Unchained Labs	\$17M	Series D	Laboratory instruments	Pleasanton
2018	SafeTraces	\$10M	Series A	Edible barcode technology	Pleasanton
2017	Ankon Medical Tech	\$100M	Late Stage	Gastric diagnostic device	Pleasanton
2017	Purigen Biosystems	\$21M	Series A	DNA sample prep	Pleasanton
2017	POC Medical Systems	\$21M	Series A	Point-of-care cancer diagnostics	Livermore
2016	HealthTell	\$26M	Series B	Immune profiling	San Ramon
2016	Spirosure	\$18M	Series C	Breath-analysis disease diagnostics	Pleasanton